Pyxis Oncology, Inc. (NASDAQ:PYXS) Receives Consensus Rating of “Moderate Buy” from Analysts

Shares of Pyxis Oncology, Inc. (NASDAQ:PYXS) have been given a consensus recommendation of “Moderate Buy” by the nine research firms that are presently covering the company, MarketBeat Ratings reports. One investment analyst has rated the stock with a hold rating and eight have assigned a buy rating to the company. The average twelve-month price target among brokerages that have issued a report on the stock in the last year is $10.00.

A number of research analysts have weighed in on the stock. HC Wainwright reissued a “buy” rating and issued a $7.00 target price on shares of Pyxis Oncology in a research note on Thursday. William Blair lowered shares of Pyxis Oncology from an “outperform” rating to a “market perform” rating in a research note on Thursday. Stifel Nicolaus assumed coverage on shares of Pyxis Oncology in a research note on Thursday, August 8th. They issued a “buy” rating and a $10.00 target price on the stock. Royal Bank of Canada raised their target price on shares of Pyxis Oncology from $7.00 to $10.00 and gave the stock an “outperform” rating in a research note on Thursday. Finally, Stephens assumed coverage on shares of Pyxis Oncology in a research note on Friday, November 8th. They issued an “overweight” rating and a $13.00 target price on the stock.

Institutional Trading of Pyxis Oncology

Institutional investors have recently made changes to their positions in the company. Fullcircle Wealth LLC purchased a new stake in shares of Pyxis Oncology during the 2nd quarter valued at approximately $40,000. Intech Investment Management LLC acquired a new stake in Pyxis Oncology in the 3rd quarter valued at approximately $55,000. SG Americas Securities LLC acquired a new stake in Pyxis Oncology in the 3rd quarter valued at approximately $58,000. The Manufacturers Life Insurance Company acquired a new stake in Pyxis Oncology in the 2nd quarter valued at approximately $65,000. Finally, MetLife Investment Management LLC increased its holdings in Pyxis Oncology by 41.1% in the 3rd quarter. MetLife Investment Management LLC now owns 18,818 shares of the company’s stock valued at $69,000 after purchasing an additional 5,484 shares during the last quarter. Hedge funds and other institutional investors own 39.09% of the company’s stock.

Pyxis Oncology Stock Down 9.5 %

Shares of Pyxis Oncology stock opened at $1.90 on Monday. Pyxis Oncology has a twelve month low of $1.35 and a twelve month high of $6.85. The firm’s 50-day moving average price is $3.64 and its 200 day moving average price is $3.61.

Pyxis Oncology Company Profile

Pyxis Oncology, Inc, a clinical stage company, engages in the development of therapeutics to treat cancers. Its lead antibody-drug conjugates (ADC) product candidate is PYX-201, an investigational novel ADC consisting of human immunoglobulin G1 (IgG1), which is in Phase 1 clinical trial to treat patients with relapsed or refractory solid tumors; and lead immuno-oncology (IO) product candidate is PYX-106, an investigational fully human IgG1 Siglec-15-targeting antibody that is in Phase 1 clinical trial to treat patients with advanced solid tumors.